Search
Methotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigational[L7180] Methotrexate was granted FDA approval on 7 December 1953.[L7198] … [A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma
Synonyms: 4-amino-N(10)-methylpteroylglutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acidProducts: NORDIMET 10MG ILO I E FER, NORDIMET 15MG ILO I E FERImelasomeran
go.drugbank.com/drugs/DB17090ApprovedInvestigationalImelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine. … [L45320] It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious variant of concern first documented in 2021.[L43922]
Axicabtagene ciloleucel
go.drugbank.com/drugs/DB13915ApprovedInvestigationalAxicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. … [A216163] Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017.
Synonyms: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptorOmalizumab
go.drugbank.com/drugs/DB00043ApprovedInvestigational[A39518] Omalizumab was first approved in the US in 2003 [A263507] and in Europe in 2005. … Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE).
Products: XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/1.0ML, XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5MLNorfloxacin
go.drugbank.com/drugs/DB01059ApprovedInvestigationalA synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.
Products: NORFLOXACINA EG, N-FLOXA 200Telmisartan
go.drugbank.com/drugs/DB00966ApprovedInvestigationalTelmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. … smooth muscle, ultimately leading to a reduction in arterial blood pressure.
Mixtures: TELMISARTAN E IDROCLOROTIAZIDE EG, TELMISARTAN E IDROCLOROTIAZIDE EGCategories: Agents Acting on the Renin-Angiotensin SystemPolihexanide
go.drugbank.com/drugs/DB12277ApprovedInvestigational[A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite. … [L53003] It was initially approved in August of 2024, and is the first and only approved therapy to treat patients with _Acanthamoeba_ keratitis. [L53143]
Categories: Compounds used in a research, industrial, or household settingAfamelanotide
go.drugbank.com/drugs/DB04931Approved[L9092] Despite its relatively recent approval, afamelanotide has been available for use as an orphan drug in both the US and EU since 2008.[L9122,L9125] … [A187202,A187205] Afamelanotide is currently the only approved drug therapy used in the management of erythropoietic protoporphyria, having received approval in the EU in December 2014[L9119] and subsequent
Categories: Compounds used in a research, industrial, or household settingRiociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for … the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III.
Synonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminateSecukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque
Products: Fraizeron 150mg/ml solution for injection in pre-filled pen, Fraizeron 300mg/2ml solution for injection in pre-filled pen